279263-03-5

Basic information

• Product Name: 5-BROMO-2-ETHOXY-BENZONITRILE
• Synonyms: AKOS B005866;5-BROMO-2-ETHOXY-BENZONITRILE;Albb-008947
• CAS NO: 279263-03-5
• Molecular Formula: C9H8BrNO
• Molecular Weight: 226.07
• Mol File: 279263-03-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 82-84℃
• Boiling Point: 301.5°Cat760mmHg
• Flash Point: 136.2°C
• Appearance: /
• Density: 1.48g/cm³
• Vapor Pressure: 0.00105mmHg at 25°C
• Refractive Index: 1.571
• CAS DataBase Reference: 5-BROMO-2-ETHOXY-BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-ETHOXY-BENZONITRILE(279263-03-5)
• EPA Substance Registry System: 5-BROMO-2-ETHOXY-BENZONITRILE(279263-03-5)

Safety Data

• RIDADR: UN3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 279263-03-5(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-ethoxy-benzonitrile is a chemical compound with the molecular formula C9H8BrNO. It is a white to off-white solid that is commonly used in the pharmaceutical and agrochemical industries as an intermediate in the synthesis of various compounds. 5-BROMO-2-ETHOXY-BENZONITRILE is known for its ability to act as a building block for the production of pharmaceutical drugs and agrochemicals. It is also used in research and development to create new molecules with potential therapeutic and agricultural properties. Additionally, 5-Bromo-2-ethoxy-benzonitrile is known for its low toxicity and relatively stable nature, making it a versatile and important chemical in various industries.

InChI:InChI=1/C9H8BrNO/c1-2-12-9-4-3-8(10)5-7(9)6-11/h3-5H,2H2,1H3

Upstream product

• 74-96-4 ethyl bromide 
• 40530-18-5 5-bromo-2-hydroxybenzonitrile 
• 75-03-6 ethyl iodide 
• 79636-94-5 5-bromo-2-ethoxybenzaldehyde 

Downstream Products

• 1610416-56-2 2-ethoxy-5-(methoxymethyl)benzonitrile 

Relevant articles and documents

Permeant fluorescent probes visualize the activation of sarm1 and uncover an antineurodegenerative drug candidate

SARM1 regulates axonal degeneration through its NAD-metabolizing activity and is a drug target for neurodegenerative disorders. We designed and synthesized fluorescent conjugates of styryl derivative with pyridine to serve as substrates of SARM1, which exhibited large red shifts after conversion. With the conjugates, SARM1 activation was visualized in live cells following elevation of endogenous NMN or treatment with a cell-permeant NMN-analog. In neurons, imaging documented mouse SARM1 activation preceded vincristine-induced axonal degeneration by hours. Library screening identified a derivative of nisoldipine (NSDP) as a covalent inhibitor of SARM1 that reacted with the cysteines, especially Cys311 in its ARM domain and blocked its NMN-activation, protecting axons from degeneration. The Cryo-EM structure showed that SARM1 was locked into an inactive conformation by the inhibitor, uncovering a potential neuroprotective mechanism of dihydropyridines.

Phenylimidazole XOR (Xanthine Oxidoreductase) inhibitor and preparation and application thereof

The invention belongs to the technical field of pharmaceutical and chemical industries and discloses a phenylimidazole XOR (Xanthine Oxidoreductase) inhibitor and the preparation and the application of the phenylimidazole XOR inhibitor. The structure of t

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.